Abstract
In 2020 a subcutaneous (SC) form of infliximab was approved by EMA, allowing self-administration and preventing patient to go to the hospital for drug administration. The present study was to conduct budget impact analysis (BIA) to understand the potential financial effect of introducing SC infliximab instead of intravenous (IV) infliximab in a gastroenterology department in public hospital of Bordeaux (PHB) for the French health insurance (FHI).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
